hit counter
Can-Fite BioPharma Ltd. (CANF) Stock News Sentiment & Price - Sentifly
CANF - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Can-Fite BioPharma Ltd. (CANF)

Israel
Biotechnology
NYSE
CANF Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CANF Latest news
Business Wire
Neutral
Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
2021-10-26 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit

Benzinga
Positive
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
2021-10-21 09:25

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary Pharmacology & Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology, published an article titled “Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis" authored by Can-Fite's CEO Dr. Pnina Fishman.

Business Wire
Neutral
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
2021-10-21 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary Pharmacology & Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology, published an article titled “Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatt

Business Wire
Neutral
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
2021-10-05 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

Business Wire
Neutral
Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
2021-09-17 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences

Business Wire
Neutral
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-09 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire
Neutral
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
2021-09-02 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study

Benzinga
Negative
Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY
2021-08-26 12:48

Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021.

Business Wire
Neutral
Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update
2021-08-26 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update

Business Wire
Neutral
Can-Fite Announces $10.0 Million Registered Direct Offering
2021-08-12 08:00

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 5,000,000 of the Company's American Depositary Shares (ADSs) (or

Loading more news...